Appropriators Ask HHS To Study 340B Drug Program, Hep C Rx Costs

By John Wilkerson / December 17, 2014 at 11:53 AM
Congress' massive spending deal includes two provisions related to the debate over drug prices -- one on the 340B drug discount program and one on hepatitis C drug prices. The report accompanying the legislation urges HHS to investigate whether the most vulnerable patients benefit from the 340B program, and it asks CMS to study the prevalence of hepatitis and the cost of treating the sickest patients. The 340B program, administered by HHS' Health Resources and Services Administration, makes drug makers...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.